Skip to main content

Table 2 Demographic, current disease status, pulmonary involvement, treatment, and the cytokines serum levels of the patients with antisynthetase syndrome. Laboratory profiles of the control group

From: High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome

  ASSD
(n = 64)
Control
(n = 64)
P
IMACS set scores
 MMT-8 (0–80) 78 (71–80)  
 Patient’ VAS (0–10) 4.0 (2.0–6.0)  
 Physician’ VAS (0–10) 3.0 (0.0–5.0)  
 MYOACT (0–60) 4.0 (0.5–2.5)  
 HAQ (0.00–3.00) 0.67 (0.13–1.38)  
 CPK (U/L) 208 (98–597) 106 (78–161) < 0.001
 LDH (U/L) 352 (243–590) 346 (312–345) 0.937
 AST (U/L) 24 (17–37) 20 (16–23) 0.009
 ALT (U/L) 24 (16–57) 18 (13–25) 0.030
Lung involvements
 Ground-glass 46 (71.9)  
 Incipient pneumopathy 40 (62.5)  
 Pulmonary fibrosis 14 (21.9)  
 Pulmonary nodules 11 (17.2)  
 FVC (% predict), n = 39 62.5 (48.0–73.5)  
 FEV1 (% predicted), n = 39 64 (49–77)  
 FEV1/FVC ratio, n = 39 0.90 (0.93–1.08)  
 DLCO2 (% predicted), n = 39 61.0 (37.8–73.0)  
Treatment
 Prednisone
  Current use 46 (71.9)  
  Dose (mg/day) 10 (0–40)  
 Immunosuppressive drugs 47 (73.4)  
  Azathioprine 23 (35.9)  
  Mycophenolate mofetil 11 (17.2)  
  Methotrexate 14 (21.9)  
  Antimalarial 4 (6.3)  
  Leflunomide 2 (3.1)  
  Cyclosporine 3 (4.7)  
  Cyclophosphamide 1 (1.7)  
 Rituximab 16 (25.0)  
Cytokines
 YKL-40 (pg/mL) 538.4 (363.4–853.1) 270.0 (201.8–451.9) < 0.001
 IFNγ (pg/mL) 0.02 (0.00–1.89) 0.02 (0.00–0.17) 0.876
 TNFα (pg/mL) 48.4 (31.0–66.3) 39.6 (29.3–49.0) 0.011
  1. Data are expressed as mean ± standard deviation (SD); median (interquartile 25th - 75th) or frequency (%)
  2. ALT alanine aminotransferase; ASSD antisynthetase syndrome; AST aspartate aminotransferase; CPK creatine phosphokinase; DLCO2 diffusion of carbon dioxide; FEV1 forced expiratory volume in one second; FVC forced vital capacity; HAQ Health Assessment Questionnaire; IFN interferon; IMACS: International Myositis Assessment and Clinical Studies Group; LDH lactate dehydrogenase; MMT-8 Manual Muscle Testing; MYOACT Myositis Disease Activity Assessment Visual Analogue Scales; TNF tumor necrosis factor; VAS Visual Analog Scale; YKL chitinase-3-like-1 protein